- Commentary : Okrelizumab - benefits of five years of treatment2020 | Faculty of Medicine in Pilsen
- Ocrelizumab2018 | First Faculty of Medicine
- Highly active relapse / reminent multiple sclerosis and okrelizumab after failure of alemtuzumab treatment2020 | Faculty of Medicine in Hradec Králové
- Okrelizumab aiming at B-lymphocytes proved to be irreplaceable in the treatment of MS patients2018 | Faculty of Medicine in Hradec Králové
- Ocrelizumab in the treatment of multiple sclerosis - view of a neurologist and immunologist2018 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Commentary : Sustained reduction in disability progression in patients with primary progressive multiple sclerosis - follow-up study ORATORIO2020 | Faculty of Medicine in Pilsen
- Ocrelizumab since the first multiple sclerosis attack - a milestone in reimbursement criteria2022 | First Faculty of Medicine
- Ocrelizumab is highly effective in the treatment of multiple sclerosis. What is the immunobiological background of its clinical effectivity?2020 | Faculty of Medicine in Hradec Králové
- Early high efficacy mulitple sclerosis treatment: therapeutic success despite safety barriers2023 | First Faculty of Medicine
- Multiple sclerosis patient suitable for the treatment with ofatumumab2022 | Faculty of Medicine in Hradec Králové